Adial shareholders approve 5x authorized-share increase to 500M and new 2026 equity plans

ADIAL PHARMACEUTICALS, INC.

Authorized common shares increased from 100M to 500M (1,239,968 votes for, 37,210 against).
2026 Equity Incentive Plan approved: 3,078,147 new shares plus 196,670 returning shares and 5% annual evergreen through Jan 1, 2036.
Series F warrant exercise issuance of up to 552,940 shares approved under Nasdaq Listing Rule 5635(d).
2017 Plan share pool raised from 200,000 to 225,666 shares; ESPP approved; CBIZ CPAs ratified as auditor.
Meeting partially adjourned on 4 proposals pending Nasdaq conditional approval; reconvenes Oct 1, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.